Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases.

ABSTRACT:

Background

Dysregulated activation of the inflammasome is involved in various human diseases including acute cerebral ischemia, multiple sclerosis and sepsis. Though many inflammasome inhibitors targeting NOD-like receptor protein 3 (NLRP3) have been designed and developed, none of the inhibitors are clinically available. Growing evidence suggests that targeting apoptosis-associated speck-like protein containing a CARD (ASC), the oligomerization of which is the key event for the assembly of inflammasome, may be another promising therapeutic strategy. Lonidamine (LND), a small-molecule inhibitor of glycolysis used as an antineoplastic drug, has been evidenced to have anti-inflammation effects. However, its anti-inflammatory mechanism is still largely unknown.

Methods

Middle c

SUBMITTER: Chen C 

PROVIDER: S-EPMC9798610 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature